HNSCC, primarily developing in the mucosal linings of the mouth and throat, remains a formidable health challenge worldwide due to its aggressive nature and poor prognosis when detected late. Despite advances in oncology, recent pharmaceutical developments have struggled to meaningfully enhance five-year survival rates or improve the quality of life for patients suffering from this malignancy. Daniell underscores the urgent necessity for therapies that specifically target microbial contributors to cancer progression, paving the way for a more tailored, multifaceted treatment landscape.

Building on prior work involving a plant-based chewing gum derived from lablab beans and enriched with FRIL, a naturally occurring antiviral protein, Daniell’s study delves into the gum’s effects on key oncogenic microbes within oral environments. The three focal microorganisms—human papilloma virus (HPV), along with two bacterial species, Porphyromonas gingivalis and Fusobacterium nucleatum—are increasingly recognized not merely as coincidental inhabitants but as active facilitators in the carcinogenesis and progression of HNSCC.

HPV infection has gained particular attention due to its rapidly increasing role in oropharyngeal cancers worldwide. Epidemiological data underscore a direct correlation between HPV presence and a surge in oropharyngeal carcinoma cases. Meanwhile, P. gingivalis and F. nucleatum, anaerobic bacteria frequently present in periodontal diseases, have been implicated in exacerbating oral cancer outcomes. The persistent colonization of these bacteria is linked to inflammation-mediated tumorigenesis, diminished treatment response, and reduced survival rates, especially in the recurrent and metastatic settings.

Daniell’s team utilized clinical saliva and oral rinse samples from HNSCC patients to evaluate microbial load before and after treatment with the bioengineered gums. Remarkably, the lablab bean gum extracts containing FRIL achieved a 93% reduction in HPV levels in saliva and an 80% decrease in oral rinse samples. These antiviral properties mark a significant stride in non-invasive, patient-friendly cancer adjunct therapies aimed at directly diminishing viral oncogenic drivers.

To further enhance the therapeutic profile, the researchers introduced protegrin—an antimicrobial peptide with potent bactericidal activity—into the gum framework. Protegrin’s inclusion proved transformative, driving P. gingivalis and F. nucleatum levels down to virtually undetectable amounts following a single dose application. This selective antimicrobial effect is critically distinct from conventional cancer therapies such as radiation, which indiscriminately destroy beneficial oral microbiota and inadvertently foster opportunistic infections, notably with Candida albicans.

The significance of these findings resonates profoundly within the context of global cancer epidemiology. Lip and oral cavity cancers were ranked as the seventh leading type in incidence and mortality rates among adolescents, young adults, and middle-aged populations worldwide in 2022. Current treatment modalities often fail to address the microbial dimension of HNSCC pathogenesis, underscoring Daniell’s gum formulation as a potentially transformative prophylactic and adjuvant treatment modality.

Importantly, the gum’s specificity in targeting pathogenic microbes while sparing commensal oral flora addresses a critical shortcoming of prevailing antimicrobial approaches. Preservation of the beneficial microbiome is fundamental for maintaining oral homeostasis, immunity, and overall health. The ability to reduce carcinogenic microbes without collateral damage represents a paradigm shift in cancer supportive care.

The study’s ex vivo design—which analyzed clinical samples outside the living body—provides strong proof-of-concept evidence, but further clinical trials are imperative to translate these promising results into viable, widely accessible therapies. Daniell advocates for the advancement of this technology into human trials as adjuvant therapies alongside existing treatment regimens or as preventive measures aimed at reducing infection and transmission risks in at-risk populations.

These findings open exciting avenues for bioengineering and pharmaceutical innovation, demonstrating how natural plant-based platforms can be harnessed to develop next-generation biologics with dual antiviral and antibacterial properties. Beyond cancer, such strategies might well extend to combat microbial drivers of other chronic diseases, given the centrality of the microbiome in human health and disease.

Henry Daniell, holding the W.D. Miller Professorship in the Department of Basic & Translational Sciences, emphasizes that the gum-based delivery system’s ease of use, affordability, and targeted efficacy could profoundly democratize access to cancer adjunct therapies, especially in low-resource settings where advanced pharmaceutical interventions remain scarce.

The multidisciplinary collaboration among Penn Dental Medicine, the University of Kansas Medical Center, UCLA, and the Veterans Administration Greater Los Angeles Healthcare System highlights the compelling synergy between innovative materials science, microbiology, and clinical oncology necessary to pioneer such novel therapeutic modalities.

Funding support from the NIH, David Geffen School of Medicine at UCLA, and the National Cancer Institute Cancer Center reflects a robust commitment from leading health agencies to back groundbreaking explorations that challenge traditional paradigms and aspire to elevate patient outcomes in head and neck cancers.

As this research progresses, the prospect of mitigating cancer progression through a simple, bioengineered chewing gum merges cutting-edge scientific innovation with practical patient care, symbolizing a hopeful advance toward more effective, less toxic cancer prevention and management strategies.

Subject of Research: Human tissue samples
Article Title: Ex vivo HNSCC clinical studies using saliva and antiviral or antibacterial chewing gums reveal reduction in carcinogenic microbes
News Publication Date: 9-Feb-2026
Web References: 10.1038/s41598-026-39062-w
Keywords: Head and neck cancer, Oral cancer, Antiviral activity, Antibiotic activity, Antivirals, Saliva

Colorectal cancer, one of the leading causes of cancer-related deaths globally, is notorious for its ability to metastasize, or spread, to distant organs. Central to this process is the often-deregulated Wnt signaling pathway, a critical regulator of embryonic development and adult cell homeostasis. In healthy tissues, Wnt signaling governs normal cellular proliferation and differentiation. However, in about 80% of colorectal tumors, mutations lead to hyperactivation of this pathway, driving uncontrolled cell division and tumorigenesis. Despite its pivotal role in cancer, Wnt signaling has been a vexing therapeutic target because its inhibition risks debilitating the regeneration of essential tissues like the intestinal lining and blood cells.

The challenge, as articulated by Claudio Cantù, professor of cell and molecular biology at Linköping University and senior author of this study, lies in disentangling the pathological activation of Wnt signaling from its physiological functions. "Wnt is a double-edged sword," Cantù explains. "If you shut it down completely, you risk killing the patient by destroying normal stem cells essential for tissue renewal. But if you don’t, the cancer continues to grow relentlessly." This paradox has stalled the development of directly targeted Wnt inhibitors in clinical oncology.

The new research crackles with promise for resolving this conundrum. By investigating the intersection of developmental biology and cancer signaling, the scientists focused on TBX3—part of the T-box family of transcription factors famously required for the proper development of vertebrate limbs and hearts. Mutations in TBX3 cause rare congenital malformations, underscoring its developmental importance. Intriguingly, previous work by Cantù’s lab hinted that TBX3 also influences colorectal cancer, but its precise molecular role remained obscure.

This study deciphers that mystery by demonstrating that TBX3 physically engages with the Wnt/β-catenin transcriptional complex in colon cancer cells. The cooperative interaction modifies gene expression patterns, specifically upregulating pro-metastatic genes that empower the cancer cells to invade other tissues. Importantly, this interaction appears largely dispensable in normal intestinal stem cells, offering a therapeutic window: targeting TBX3 or its interface with Wnt signaling could selectively weaken tumor cells without collateral damage to healthy tissue.

The researchers meticulously mapped the molecular crosstalk using advanced cell biology and biochemical techniques. They showed that TBX3 recruitment to the Wnt/β-catenin complex is essential for the activation of downstream genes driving epithelial-to-mesenchymal transition (EMT), a cellular program that endows cancer cells with migratory and invasive capabilities. Blocking TBX3 expression or disrupting its interaction with Wnt components significantly reduced metastatic behavior in experimental models, underpinning its potential as a drug target.

Beyond elucidating the biological underpinnings of metastasis, these findings hold profound therapeutic implications. Current colorectal cancer treatments struggle to curtail metastatic spread, which is the primary cause of mortality in affected patients. Novel strategies capable of selectively targeting the TBX3-Wnt axis may offer more precise interventions, minimizing systemic toxicity and preserving intestinal stem cell function. As Cantù articulates, "Our work reveals a vulnerability in cancer cells that spares normal stem cells—this is a major step toward safer and more effective therapies."

Further bolstering these conclusions, the international collaboration includes contributions from research groups in Japan, Russia, and Switzerland, reflecting a global commitment to combating metastatic colorectal cancer through innovative science. Funding from prominent institutions such as the Swedish Cancer Society and the Knut and Alice Wallenberg Foundation underscores the high priority assigned to unraveling these complex molecular pathways.

Technically, the study employed chromatin immunoprecipitation sequencing (ChIP-seq) to identify genomic regions jointly bound by TBX3 and β-catenin. These regulatory sites corresponded to genes implicated in metastasis, linking the biochemical interaction to functional gene expression changes. Complementary functional assays validated that disrupting TBX3 impairs cancer cell invasiveness and colony formation, hallmark metrics of malignancy.

The nuanced understanding of TBX3’s role enriches the broader perspective of cancer as a disease of developmental dysregulation. Tumor cells frequently co-opt embryonic signaling modules to gain growth advantages, and this research exemplifies how a developmental transcription factor can be repurposed in oncogenesis. Notably, TBX3’s evolutionary conservation—from dinosaurs to humans—underscores the deep biological roots of these pathways.

As the scientific community continues to grapple with the challenge of metastasis, the implications of this discovery extend beyond colorectal cancer. Wnt signaling and TBX family transcription factors operate across diverse tissues and cancer types, suggesting that similar mechanisms may be at play elsewhere. The concept of selectively uncoupling pathological signaling from physiological function may herald a paradigm shift in cancer therapeutics.

In sum, this compelling investigation unveils TBX3 as a pivotal modulator of Wnt-driven metastatic gene expression in colorectal cancer. By delineating a cancer-specific interaction that can be targeted clinically without damaging indispensable stem cells, it opens promising avenues for innovative anti-metastatic treatments. Such breakthroughs bring hope to thousands of patients worldwide and exemplify the power of integrating developmental biology insights into cancer research.

Subject of Research: Cells

Article Title: The Developmental Factor TBX3 Engages with the Wnt/β-catenin Transcriptional Complex in Colorectal Cancer to Regulate Metastasis Genes

News Publication Date: 9-May-2025

Web References: http://dx.doi.org/10.1073/pnas.2419691122

References: Amaia Jauregi-Miguel, Simon Söderholm, Tamina Weiss et al., Proceedings of the National Academy of Sciences (PNAS), 2025

Image Credits: Ulrik Svedin/Linköping University

Keywords: colorectal cancer, TBX3, Wnt signaling, metastasis, β-catenin, stem cells, developmental biology, transcription factors, cancer therapeutics, molecular interaction, epithelial-to-mesenchymal transition